The Timespan project started on 1 April 2021 and shall last until 31 March 2026. During this time, ADHD Europe gave input as described below with our member organisation, ADDISS and assisted in dissemination activites by sharing information on our European communication channels and more. Funding for this project was awarded via the  European Union’s Horizon 2020 research and innovation programme under the Grant agreement ID: 965381.

The Timespan Project aims to advance the management of patients with attention deficit hyperactivity disorder (ADHD) and co-occurring cardiometabolic disease by improving available treatments and risk stratification. The two conditions share substantial comorbidity and common genetics, with cardiometabolic disease leading to premature deaths and placing a substantial burden on healthcare systems. Moreover, the co-existence of psychiatric disorders in patients with this profile cannot be overlooked. The project’s work is expected to improve the clinical outcomes as well as the quality of life of adult ADHD patients with co-occurring cardiometabolic disease.

Andrea Bilbow, past President of ADHD Europe (2014-2020) was responsible for the collaboration of ADDISS (national organisation based in UK, partner of the research consortium) and our ourselves ADHD Europe during the timeframe of the project to make TIMESPAN results accessible in clear and customized formats to reach the scientific, clinical and public health community, guideline committees and the general public, particularly focusing on patient groups across Europe.

ADHD Europe attendance when required at relevant other scientific conferences as a platform for showcasing TIMESPAN results. The following yearly scientific conferences are known to date as potential platforms for TIMESPAN talks, posters and symposia (Eunethydis, ECNP, World Congress on ADHD, World Congress of Psychiatric Genetics, European Congress on Obesity, European Society of Cardiology congress, UK Adult ADHD Network, International Conference on Pharmaco-epidemiology & Therapeutic Risk Management, Asian Conference on Pharmacoepidemiology, International Society of Pharmacovigilance).

WP1 – Epidemiology: The consequences of ADHD on the management, disease progression and prognosis of cardiometabolic diseases in adults -Lead: Catharina Hartman UMCG

WP2- Study the effectiveness and safety of ADHD medication and combined pharmacotherapy in individuals with ADHD and cardiometabolic diseas – Lead: Zheng Chang KI

WP3 – Characterize the level of treatment discontinuity across the adult lifespan in individuals with ADHD and cardiometabolic disease – Lead: Kari Klungsøyr UiB

WP4 – Identify genetic risk factors for medication treatment discontinuity in ADHD patients –
Lead: Ditte Demontis AU

WP5 – ADHD Remote Technology (ART) study of cardiometabolic risk factors and medication adherence // Short title: ART-CARMA – Lead: Jonna Kuntsi KCL

WP6 – Predictive Modelling of Cardiometabolic Outcomes and Treatment Discontinuity – Lead: Stephen Faraone SUNY

WP7 – Ethics and Data Management – Lead: Patrick Ip HKU

WP8 – Dissemination, communication, exploitation, guideline development, and training – Lead: Veronika Pičmanová concentris, Co-Lead: Josep Antoni RamosQuiroga VHIR

WP9 Project Management – Lead: Henrik Larsson ORU

W10 – Ethics requirements Lead: Henrik Larsson ORU

Website: www.timespan.eu
Twitter: @TIMESPAN_H2020
LinkedIn: TimespanHorizon2020
Facebook: TIMESPAN_h2020